Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004380 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
A Phase 1 study of Epithelial Ovarian Cancer, sponsored by Morphotek.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT01004380: Completed Phase 1 study of Epithelial Ovarian Cancer, sponsored by Morphotek.
NCT01004380 is a Phase 1 study of Epithelial Ovarian Cancer that has completed, run by Morphotek. The registered enrollment target is 15 participants, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01004380, a Phase 1 study of Epithelial Ovarian Cancer, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
Conditions Studied
Interventions
- DRUG Farletuzumab, Carboplatin, and PLD
Study Locations (5)
Alabama
- University of Alabama at Birmingham Medical Center - Birmingham
Maryland
- Johns Hopkins University - Baltimore
New York
- Schwartz Gynecologic Oncology - Brightwaters
Tennessee
- Chattanooga GYN Oncology - Chattanooga
Texas
- International Beneficence Clinical Research, LLC - Harlingen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-11 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
What the finished NCT01004380 record still lists
NCT01004380 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 211-participant average among 41 other Epithelial Ovarian Cancer trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Epithelial Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Farletuzumab, Carboplatin, and PLD is the first listed.
NCT01004380 lists 5 locations in 5 states (Alabama, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT01004380 about?
NCT01004380 is a clinical study titled "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer". The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
What is the current status of trial NCT01004380?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-11. Estimated completion is 2012-10.
What conditions does trial NCT01004380 study?
This clinical trial studies the following conditions: Epithelial Ovarian Cancer.
What interventions are being tested in trial NCT01004380?
The interventions under investigation include: Farletuzumab, Carboplatin, and PLD (DRUG).
Who is sponsoring clinical trial NCT01004380?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01004380 being conducted?
This trial has 5 study locations across Alabama, Maryland, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epithelial Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01004380's enrollment target sits among peer trials
15 40th of 41 higher than 2 of 41 other Epithelial Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epithelial Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
T-regulatory Cell Depletion with E7777 Combined with Pembrolizumab in Recurrent or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
RECRUITING · Phase 1
-
CT-95 in Advanced Cancers Associated With Mesothelin Expression
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia